YSCH-01
Phase 2Small molecule
YSCH-01 is one of 65 small molecule programs targeting NSCLC. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
57 competitors in NSCLC
#DrugCompanyPhaseTrials
1Iressa
AstraZenecaApproved
Keytruda
Merck & Co.Phase 3
Taxotere
AAvyxa
Phase 3
Alimta
SShawn Eagle
Phase 3
Navmi
SSummit Therapeutics
Phase 3
Taxol
TevaPhase 2
Alecensa
RochePhase 2
Tecentriq
RochePhase 2
Libtayo
RegeneronPhase 2
SYS6010
CCSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Rare Tumor1 trial
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
Not yet recruiting·—·Phase 1/2·NCT07307053·600 enrolled
NSCLC1 trial
An Open-label, Single-center Study to Evaluate the Dose Escalation and Cohort Expansion of YSCH-01 in Subjects With Pulmonary Metastasis of Advanced Solid Tumors and Advanced Non-small Cell Lung Cancer by Nebulized Inhalation Administration
Recruiting·CCancer Institute and Hospital, Chinese Academy of Medical Sciences·Phase 1·NCT07793500·36 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for YSCH-01. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details